Yuxi Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuxi Su has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Guoxin Nan
Department of Pediatric Research Institute Children's Hospital of Chongqing Medical University Chongqing China
2 shared publications Shaoshan Liu
Orthopedics Department, Children's Hospital of Chongqing Medical University
2 shared publications- Shifeng Huang
Orthopedic Department II, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, the Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
2 shared publications Tongchuan He
Department II of Orthopaedics, Stem Cell Biology and Therapy Laboratory, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation base of Child development and Critical Disorders, the Children's Hospital of Chongqing Medical University, Chongqing, China
2 shared publications- Bai-Cheng He
Department of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing 400016, China
1 shared publication Bo He
1 shared publication
Latest Publications
- Open Access
- 13 January 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (3) , sfaf011
Risk factors for steroid-induced osteonecrosis of the femoral head in children with immune kidney disease
Objective: To investigate the risk factors for steroid-induced osteonecrosis of the femoral head (SONFH) after glucocorticoid (GC) therapy in children with immune kidney diseases. Methods: This retrospective study included patients (1–18 years) diagnosed with immune kidney disease treated with GCs from January 2012 to July 2022 in our hospital. Data, such as sex, age and body weight at the first GC treatment, and the GC dose, were collected. Patients were divided into SONFH and non-SONFH groups based on the occurrence of SONFH. According to the International Classification of Diseases, Tenth Revision, the disease diagnosis was searched on the clinical data webpage of our hospital. The descriptive statistics and binary logistic regression analyses were performed. A nomogram was constructed to predict the risk of SONFH in children with immune kidney disease after GC treatment. The predictive ability of the nomogram was evaluated using the concordance index and calibration plots. Results: The SONFH and non-SONFH groups included 18 and 90 patients, respectively. Age at first GC treatment, 6-month cumulative [oral (po) plus intravenous (iv)] GC dose, total cumulative prednisone (po) dose, total cumulative methylprednisolone (iv) dose for pulse therapy and total cumulative GC (po plus iv) dose significantly differed between the two groups. Age at the initial GC treatment, total cumulative prednisone (po) dose and total cumulative methylprednisolone (iv) dose for pulse therapy were independent risk factors for SONFH in the multivariate analysis. Conclusions: This study identified specific risk factors for developing SONFH during GC treatment. Thus, children with immune kidney disease undergoing GC treatment should be monitored closely based on these risk factors, with the aim to avoid irreversible damage to the femoral head.
- 13 January 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (3) , sfaf011
Open AccessRisk factors for steroid-induced osteonecrosis of the femoral head in children with immune kidney disease
Objective: To investigate the risk factors for steroid-induced osteonecrosis of the femoral head (SONFH) after glucocorticoid (GC) therapy in children with immune kidney diseases. Methods: This retrospective study included patients (1–18 years) diagnosed with immune kidney disease treated with GCs from January 2012 to July 2022 in our hospital. Data, such as sex, age and body weight at the first GC treatment, and the GC dose, were collected. Patients were divided into SONFH and non-SONFH groups based on the occurrence of SONFH. According to the International Classification of Diseases, Tenth Revision, the disease diagnosis was searched on the clinical data webpage of our hospital. The descriptive statistics and binary logistic regression analyses were performed. A nomogram was constructed to predict the risk of SONFH in children with immune kidney disease after GC treatment. The predictive ability of the nomogram was evaluated using the concordance index and calibration plots. Results: The SONFH and non-SONFH groups included 18 and 90 patients, respectively. Age at first GC treatment, 6-month cumulative [oral (po) plus intravenous (iv)] GC dose, total cumulative prednisone (po) dose, total cumulative methylprednisolone (iv) dose for pulse therapy and total cumulative GC (po plus iv) dose significantly differed between the two groups. Age at the initial GC treatment, total cumulative prednisone (po) dose and total cumulative methylprednisolone (iv) dose for pulse therapy were independent risk factors for SONFH in the multivariate analysis. Conclusions: This study identified specific risk factors for developing SONFH during GC treatment. Thus, children with immune kidney disease undergoing GC treatment should be monitored closely based on these risk factors, with the aim to avoid irreversible damage to the femoral head.
- 1 February 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B (2) , 212-218
The necessity of ulnar nerve exploration and translocation in open reduction of medial humeral epicondyle fractures in children
Aims: Medial humeral epicondyle fractures (MHEFs) are common elbow fractures in children. Open reduction should be performed in patients with MHEF who have entrapped intra-articular fragments as well as displacement. However, following open reduction, transposition of the ulnar nerve is disputed. The aim of this study is to evaluate the need for ulnar nerve exploration and transposition.Methods: This was a retrospective cohort study. The clinical data of patients who underwent surgical treatment of MHEF in our hospital from January 2015 to January 2022 were collected. The patients were allocated to either transposition or non-transposition groups. Data for sex, age, cause of fracture, duration of follow-up, Papavasiliou and Crawford classification, injury-to-surgery time, preoperative ulnar nerve symptoms, intraoperative exploration of ulnar nerve injury, surgical incision length, intraoperative blood loss, postoperative ulnar nerve symptoms, complications, persistent ulnar neuropathy, and elbow joint function were analyzed. Binary logistic regression analysis was used for statistical analysis.Results: A total of 124 patients were followed up, 50 in the ulnar nerve transposition group and 74 in the non-transposition group. There were significant differences in ulnar nerve injury (p = 0.009), incision length (p < 0.001), and blood loss (p = 0.003) between the two groups. Binary logistic regression analysis revealed that preoperative ulnar nerve symptoms (p = 0.012) were risk factors for postoperative ulnar nerve symptoms. In addition, ulnar nerve transposition did not affect the occurrence of postoperative ulnar nerve symptoms (p = 0.468).Conclusion: Ulnar nerve transposition did not improve clinical outcomes. It is recommended that the ulnar nerve should not be transposed when treating MHEF operatively.Cite this article: Bone Joint J 2024;106-B(2):212–218.
- 1 February 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B (2) , 212-218
The necessity of ulnar nerve exploration and translocation in open reduction of medial humeral epicondyle fractures in children
Aims: Medial humeral epicondyle fractures (MHEFs) are common elbow fractures in children. Open reduction should be performed in patients with MHEF who have entrapped intra-articular fragments as well as displacement. However, following open reduction, transposition of the ulnar nerve is disputed. The aim of this study is to evaluate the need for ulnar nerve exploration and transposition.Methods: This was a retrospective cohort study. The clinical data of patients who underwent surgical treatment of MHEF in our hospital from January 2015 to January 2022 were collected. The patients were allocated to either transposition or non-transposition groups. Data for sex, age, cause of fracture, duration of follow-up, Papavasiliou and Crawford classification, injury-to-surgery time, preoperative ulnar nerve symptoms, intraoperative exploration of ulnar nerve injury, surgical incision length, intraoperative blood loss, postoperative ulnar nerve symptoms, complications, persistent ulnar neuropathy, and elbow joint function were analyzed. Binary logistic regression analysis was used for statistical analysis.Results: A total of 124 patients were followed up, 50 in the ulnar nerve transposition group and 74 in the non-transposition group. There were significant differences in ulnar nerve injury (p = 0.009), incision length (p < 0.001), and blood loss (p = 0.003) between the two groups. Binary logistic regression analysis revealed that preoperative ulnar nerve symptoms (p = 0.012) were risk factors for postoperative ulnar nerve symptoms. In addition, ulnar nerve transposition did not affect the occurrence of postoperative ulnar nerve symptoms (p = 0.468).Conclusion: Ulnar nerve transposition did not improve clinical outcomes. It is recommended that the ulnar nerve should not be transposed when treating MHEF operatively.Cite this article: Bone Joint J 2024;106-B(2):212–218.
- 16 May 2023
- Published by Elsevier in Hand Surgery and Rehabilitation
- Vol. 42 (4) , 326-331
Delayed open surgery for distal radius epiphyseal plate fracture in children
- 16 May 2023
- Published by Elsevier in Hand Surgery and Rehabilitation
- Vol. 42 (4) , 326-331
Delayed open surgery for distal radius epiphyseal plate fracture in children
- Open Access
- 14 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Risk factors of developmental dysplasia of the hip in a single clinical center
Developmental dysplasia of the hip (DDH) is the main cause of early-onset hip osteoarthritis in adulthood. Early screening of DDH is the key to avoiding these severe complications. This study aimed to assure the risk factors are suitable for screening patients with DDH in our region. We retrospectively analyzed 10,668 patients (21,336 hips) at our hospital. Overall, 204 patients with pathological DDH and 408 patients with normal hips were included in this study. All patients were diagnosed by performing ultrasound examinations according to the Graf technique. The risk factors were assessed based on patients’ clinical data. Pearson’s chi-square or Fisher’s exact tests and multivariate logistic regression analysis were performed for statistical analysis. A total of 204 patients were diagnosed with pathologic DDH and were treated with the Pavlik harness. Among these, 184 patients were female. There were 73 cases of first birth, 13 had oligohydramnios, 13 had foot deformity, 31 had breech delivery, 6 had congenital muscular torticollis. Female sex, vaginal delivery, breech presentation, oligohydramnios and foot deformity were identified as the risk factors for DDH. The risk factors of DDH in our clinical center were confirmed in our clinical center, this can supply the screening advice for the doctors.
- 14 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Open AccessRisk factors of developmental dysplasia of the hip in a single clinical center
Developmental dysplasia of the hip (DDH) is the main cause of early-onset hip osteoarthritis in adulthood. Early screening of DDH is the key to avoiding these severe complications. This study aimed to assure the risk factors are suitable for screening patients with DDH in our region. We retrospectively analyzed 10,668 patients (21,336 hips) at our hospital. Overall, 204 patients with pathological DDH and 408 patients with normal hips were included in this study. All patients were diagnosed by performing ultrasound examinations according to the Graf technique. The risk factors were assessed based on patients’ clinical data. Pearson’s chi-square or Fisher’s exact tests and multivariate logistic regression analysis were performed for statistical analysis. A total of 204 patients were diagnosed with pathologic DDH and were treated with the Pavlik harness. Among these, 184 patients were female. There were 73 cases of first birth, 13 had oligohydramnios, 13 had foot deformity, 31 had breech delivery, 6 had congenital muscular torticollis. Female sex, vaginal delivery, breech presentation, oligohydramnios and foot deformity were identified as the risk factors for DDH. The risk factors of DDH in our clinical center were confirmed in our clinical center, this can supply the screening advice for the doctors.
- Open Access
- 28 October 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 882813
Radial and ulnar medullary canal diameter in children: Anatomical limitations of elastic stable intramedullary nailing
Introduction: Surgery is inevitable for children who cannot achieve the ideal reduction in forearm fractures. The biggest limitation of the elastic stable intramedullary nail (ESIN) fixation method is the diameter of the medullary canal. This study aimed to measure the medullary canal diameters of the radius and ulna at different ages in children.Methods: The forearm radiographs of 540 children were retrospectively reviewed. All background characteristics, including weight, sex, maturity of the radius and ulna, and length of the radius and ulna, were measured and recorded. Children with radius and ulnar diameters shorter than 2 mm were analyzed by statistical regression analysis by SPSS software.Results: When we set 2 mm as the minimum medullary canal diameter, our results showed that patients aged 3–12 years had radius and ulnar diameters under this limit. The regression analysis of risk factors with the 2 mm diameter limitation had significant differences based on age (P = 0.006) and sex (P = 0.033). There was no significant difference between patients based on weight (P = 0.056), ulnar length (P = 0.946), radius length (P = 0.503), radius maturity (P = 0.655), or ulnar maturity (P = 0.774).Conclusions: The average medullary canal diameter remained constant until 12 years of age. However, the average diameter length did not increase significantly after the age of 12 years. The incidence of medullary canal diameter shorter than 2 mm was correlated with age and sex. Our results suggest that surgeons should pay attention to the medullary diameter of the anteroposterior and lateral radiographs to determine the ESIN diameter.
- 28 October 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 882813
Open AccessRadial and ulnar medullary canal diameter in children: Anatomical limitations of elastic stable intramedullary nailing
Introduction: Surgery is inevitable for children who cannot achieve the ideal reduction in forearm fractures. The biggest limitation of the elastic stable intramedullary nail (ESIN) fixation method is the diameter of the medullary canal. This study aimed to measure the medullary canal diameters of the radius and ulna at different ages in children.Methods: The forearm radiographs of 540 children were retrospectively reviewed. All background characteristics, including weight, sex, maturity of the radius and ulna, and length of the radius and ulna, were measured and recorded. Children with radius and ulnar diameters shorter than 2 mm were analyzed by statistical regression analysis by SPSS software.Results: When we set 2 mm as the minimum medullary canal diameter, our results showed that patients aged 3–12 years had radius and ulnar diameters under this limit. The regression analysis of risk factors with the 2 mm diameter limitation had significant differences based on age (P = 0.006) and sex (P = 0.033). There was no significant difference between patients based on weight (P = 0.056), ulnar length (P = 0.946), radius length (P = 0.503), radius maturity (P = 0.655), or ulnar maturity (P = 0.774).Conclusions: The average medullary canal diameter remained constant until 12 years of age. However, the average diameter length did not increase significantly after the age of 12 years. The incidence of medullary canal diameter shorter than 2 mm was correlated with age and sex. Our results suggest that surgeons should pay attention to the medullary diameter of the anteroposterior and lateral radiographs to determine the ESIN diameter.
- 16 July 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 119 (11) , 9462-9473
Wnt11 promotes BMP9‐induced osteogenic differentiation through BMPs/Smads and p38 MAPK in mesenchymal stem cells
Bone morphogenetic protein 9 (BMP9), as one of the most potent osteogenic factors, is a promising cytokine for bone tissue engineering. Wnt11 can regulate the development of the skeletal system and is related to high bone mass syndrome. However, the effect of Wnt11 on BMP9‐induced osteogenic differentiation remains unknown. In this study, we investigated the relationship between Wnt11‐ and BMP9‐induced osteogenic differentiation in mesenchymal stem cells (MSCs). We recapitulated the osteogenic potential of BMP9 in C3H10T1/2 cells. The messenger RNA expression of Wnt11 is detectable in the available progenitor cells, and BMP9 can obviously increase the protein level of Wnt11 in these cells. Exogenous Wnt11 potentiates the effect of BMP9 on increasing alkaline phosphatase (ALP) activities, the expression of osteopontin (OPN), and Runt‐related transcription factor 2 (Runx2), so does matrix mineralization in C3H10T1/2 cells. Although Wnt11 cannot increase the BMP9‐induced ectopic bone formation, it can increase the bone density induced by BMP9 apparently. Wnt11 increases the level of p‐Smad1/5/8, as well as p‐p38. Meanwhile, Wnt11 promotes the effect of BMP9 on increasing the levels of p‐Smad1/5/8 and p‐p38. Inhibition of p38 decreases the BMP9‐induced ALP activities, the expression of OPN, and the mineralization in C3H10T1/2 cells. However, all of these effects of the p38 inhibitor on BMP9‐induced osteogenic markers can be almost reversed by the overexpression of Wnt11. Our findings suggested that Wnt11 can enhance the osteogenic potential of BMP9 in MSCs, and this effect may be partly mediated through enhancing BMPs/Smads and the p38 MAPK signal, which was induced by BMP9.
- 16 July 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 119 (11) , 9462-9473
Wnt11 promotes BMP9‐induced osteogenic differentiation through BMPs/Smads and p38 MAPK in mesenchymal stem cells
Bone morphogenetic protein 9 (BMP9), as one of the most potent osteogenic factors, is a promising cytokine for bone tissue engineering. Wnt11 can regulate the development of the skeletal system and is related to high bone mass syndrome. However, the effect of Wnt11 on BMP9‐induced osteogenic differentiation remains unknown. In this study, we investigated the relationship between Wnt11‐ and BMP9‐induced osteogenic differentiation in mesenchymal stem cells (MSCs). We recapitulated the osteogenic potential of BMP9 in C3H10T1/2 cells. The messenger RNA expression of Wnt11 is detectable in the available progenitor cells, and BMP9 can obviously increase the protein level of Wnt11 in these cells. Exogenous Wnt11 potentiates the effect of BMP9 on increasing alkaline phosphatase (ALP) activities, the expression of osteopontin (OPN), and Runt‐related transcription factor 2 (Runx2), so does matrix mineralization in C3H10T1/2 cells. Although Wnt11 cannot increase the BMP9‐induced ectopic bone formation, it can increase the bone density induced by BMP9 apparently. Wnt11 increases the level of p‐Smad1/5/8, as well as p‐p38. Meanwhile, Wnt11 promotes the effect of BMP9 on increasing the levels of p‐Smad1/5/8 and p‐p38. Inhibition of p38 decreases the BMP9‐induced ALP activities, the expression of OPN, and the mineralization in C3H10T1/2 cells. However, all of these effects of the p38 inhibitor on BMP9‐induced osteogenic markers can be almost reversed by the overexpression of Wnt11. Our findings suggested that Wnt11 can enhance the osteogenic potential of BMP9 in MSCs, and this effect may be partly mediated through enhancing BMPs/Smads and the p38 MAPK signal, which was induced by BMP9.
- Open Access
Dietary Flavonols Intake and Risk of Esophageal and Gastric Cancer: A Meta-Analysis of Epidemiological Studies
Background: Esophageal cancer (EC) and gastric cancer (GC) are common cancers and leading causes of cancer deaths worldwide. Many studies have investigated the association between dietary flavonols intake and the risk of EC and GC, but the results are inconsistent. Hence, we conducted a systematic analysis of relevant population-based studies to assess the association and derive a more precise estimation. Methods: The Cochrane, PubMed and Embase databases were searched to identify articles published through January 2016 that met the predetermined inclusion criterion. Twelve studies involving 4593 patients and 519,378 controls were included. Results: The summary odds ratios (ORs) of EC, GC and the two combined were respectively 0.88 (95% CI: 0.73–1.08), 0.80 (95% CI: 0.70–0.91) and 0.83 (95% CI: 0.74–0.92) for the highest category of dietary flavonols intake compared with the lowest. No significant heterogeneities were observed in these studies. Further analysis showed that the pooled ORs of EC and GC for cohort, population-based case-control and hospital-based case-control studies were 0.90 (95% CI: 0.61–1.34), 0.92 (95% CI: 0.72–1.18), 0.68 (95% CI: 0.38–1.24) and 0.83 (95% CI: 0.65–1.06), 0.84 (95% CI: 0.45–1.59), 0.70 (95% CI: 0.56–0.88). The subgroup analyses revealed a significant association of flavonol intake with a reduced risk of noncardia gastric adenocarcinoma but not gastric cardia adenocarcinoma. Moreover, significant inverse associations of flavonol intake with GC risk were observed in women but not in men, in smokers but not in nonsmokers, in European populations but not in American populations. Similarly, a significant inverse association of flavonols intake with EC risk was also observed in smokers but not in nonsmokers. Conclusion: High intake of dietary flavonols is significantly related to a reduced risk of GC, especially in women and smokers.
Open AccessDietary Flavonols Intake and Risk of Esophageal and Gastric Cancer: A Meta-Analysis of Epidemiological Studies
Background: Esophageal cancer (EC) and gastric cancer (GC) are common cancers and leading causes of cancer deaths worldwide. Many studies have investigated the association between dietary flavonols intake and the risk of EC and GC, but the results are inconsistent. Hence, we conducted a systematic analysis of relevant population-based studies to assess the association and derive a more precise estimation. Methods: The Cochrane, PubMed and Embase databases were searched to identify articles published through January 2016 that met the predetermined inclusion criterion. Twelve studies involving 4593 patients and 519,378 controls were included. Results: The summary odds ratios (ORs) of EC, GC and the two combined were respectively 0.88 (95% CI: 0.73–1.08), 0.80 (95% CI: 0.70–0.91) and 0.83 (95% CI: 0.74–0.92) for the highest category of dietary flavonols intake compared with the lowest. No significant heterogeneities were observed in these studies. Further analysis showed that the pooled ORs of EC and GC for cohort, population-based case-control and hospital-based case-control studies were 0.90 (95% CI: 0.61–1.34), 0.92 (95% CI: 0.72–1.18), 0.68 (95% CI: 0.38–1.24) and 0.83 (95% CI: 0.65–1.06), 0.84 (95% CI: 0.45–1.59), 0.70 (95% CI: 0.56–0.88). The subgroup analyses revealed a significant association of flavonol intake with a reduced risk of noncardia gastric adenocarcinoma but not gastric cardia adenocarcinoma. Moreover, significant inverse associations of flavonol intake with GC risk were observed in women but not in men, in smokers but not in nonsmokers, in European populations but not in American populations. Similarly, a significant inverse association of flavonols intake with EC risk was also observed in smokers but not in nonsmokers. Conclusion: High intake of dietary flavonols is significantly related to a reduced risk of GC, especially in women and smokers.
- 1 January 2016
- Vol. 25 (3) , 578-88
Coffee consumption and risk of gastric cancer: an updated meta-analysis.
Coffee is one of the most widely consumed beverages worldwide, and many studies have investigated the association between coffee consumption and gastric cancer. However, the results are inconsistent. We conducted a systematic analysis of relevant population studies to derive a more precise estimation. Cochrane library, PubMed and Embase databases were searched to identify studies that met predetermined inclusion criterion through July 2014. All epidemiologic studies regarding coffee consumption and gastric cancer risk were selected, and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Twenty two studies (9 cohort and 13 case-control studies) involving 7,631 cases and 1,019,693 controls were included. The summary RR of gastric cancer was 0.94 (95% CI: 0.80-1.10) for the highest category of coffee consumption compared with the lowest category, and 0.93 (95% CI: 0.88-0.99) for coffee drinkers compared with nondrinkers. We stratified the population by coffee consumption. The pooled RR for the population with <1 cup/day, 1-2 cups/day and 3-4 cups/day coffee consumption compared with nondrinkers were 0.95 (95% CI: 0.84-1.08), 0.92 (95% CI: 0.82-1.03) and 0.88 (95% CI: 0.76-1.02), respectively, indicating that an increase in coffee consumption was associated with a decreased risk of gastric cancer. Furthermore, we stratified the studies by design, sex, population and time. A significant association between coffee intake and decreased gastric cancer risk was shown in case-control studies (RR=0.85, 95% CI: 0.77-0.95) and among the studies published over the last ten years (RR=0.88, 95% CI: 0.77-1.00). Our meta-analysis suggested that coffee consumption might be associated with a decreased risk of gastric cancer.
- 1 January 2016
- Vol. 25 (3) , 578-88
Coffee consumption and risk of gastric cancer: an updated meta-analysis.
Coffee is one of the most widely consumed beverages worldwide, and many studies have investigated the association between coffee consumption and gastric cancer. However, the results are inconsistent. We conducted a systematic analysis of relevant population studies to derive a more precise estimation. Cochrane library, PubMed and Embase databases were searched to identify studies that met predetermined inclusion criterion through July 2014. All epidemiologic studies regarding coffee consumption and gastric cancer risk were selected, and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Twenty two studies (9 cohort and 13 case-control studies) involving 7,631 cases and 1,019,693 controls were included. The summary RR of gastric cancer was 0.94 (95% CI: 0.80-1.10) for the highest category of coffee consumption compared with the lowest category, and 0.93 (95% CI: 0.88-0.99) for coffee drinkers compared with nondrinkers. We stratified the population by coffee consumption. The pooled RR for the population with <1 cup/day, 1-2 cups/day and 3-4 cups/day coffee consumption compared with nondrinkers were 0.95 (95% CI: 0.84-1.08), 0.92 (95% CI: 0.82-1.03) and 0.88 (95% CI: 0.76-1.02), respectively, indicating that an increase in coffee consumption was associated with a decreased risk of gastric cancer. Furthermore, we stratified the studies by design, sex, population and time. A significant association between coffee intake and decreased gastric cancer risk was shown in case-control studies (RR=0.85, 95% CI: 0.77-0.95) and among the studies published over the last ten years (RR=0.88, 95% CI: 0.77-1.00). Our meta-analysis suggested that coffee consumption might be associated with a decreased risk of gastric cancer.